rs1553193910
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_001854.4(COL11A1):c.4547G>T(p.Gly1516Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1516D) has been classified as Likely pathogenic.
Frequency
Consequence
NM_001854.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL11A1 | NM_001854.4 | c.4547G>T | p.Gly1516Val | missense_variant | 61/67 | ENST00000370096.9 | NP_001845.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL11A1 | ENST00000370096.9 | c.4547G>T | p.Gly1516Val | missense_variant | 61/67 | 1 | NM_001854.4 | ENSP00000359114.3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 38
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Marshall syndrome;C1858084:Stickler syndrome type 2;C4760307:Hearing loss, autosomal dominant 37 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Center of Genomic medicine, Geneva, University Hospital of Geneva | Sep 11, 2020 | - - |
COL11A1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 26, 2024 | The COL11A1 c.4547G>T variant is predicted to result in the amino acid substitution p.Gly1516Val. This variant has been reported in two individuals with Marshall/Stickler syndrome/isolated hearing loss (reported as G988V; Annunen et al. 1999. PubMed ID: 10486316; reported as de novo, Van Heurck et al. 2021. PubMed ID: 34440452). This variant affects a Gly residue of the conserved Gly-Xaa-Yaa triple helical domain (amino acid residues 529-1542, www.uniprot.org/uniprotkb/P12107/), where substitutions of glycine are usually pathogenic (Richards et al. 2010. PubMed ID: 20513134; https://www.ncbi.nlm.nih.gov/books/NBK1302/). This variant has not been reported in a large population database, indicating it is rare. This variant is interpreted as pathogenic. - |
Marshall syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Center For Human Genetics And Laboratory Diagnostics, Dr. Klein, Dr. Rost And Colleagues | Nov 09, 2017 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 23, 2018 | - - |
Stickler syndrome type 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | DASA | Feb 05, 2022 | The c.4547G>T;p.(Gly1516Val) missense variant has been observed in affected individual(s) and ClinVar contains an entry for this variant (PMID: 20513134) - PS4_supporting. The variant is located in a mutational hot spot and/or critical and well-established functional domain (collagen helix of α1(XI) collagen) - PM1. This variant is not present in population databases (rs1553193910; gnomAD; ABraOM no frequency - http://abraom.ib.usp.br/) - PM2. Multiple lines of computational evidence support a deleterious effect on the gene or gene product - PP3. In summary, the currently available evidence indicates that the variant is likely pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at